Another novel bispecific T-cell engager for the R/R group of patients bringing hope to patients who have exhausted treatment options. This one targets a very small group of T cells and hopefully the side effects (tumour lysis, possible ICANS) will be minimised.
Short video of almost 2 minutes
vjhemonc.com/video/o_fdwkhb...
Jackie